[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68: 394-424.
[2] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. J Hepatol, 2018, 69: 182-236.
[3] Lok AS, Sterling RK, Everhart JE, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology, 2010, 138: 493-502.
[4] 关贵文, 姚明解, 钱相君, 等. AFP和AFP-L3%联合检测在肝细胞癌诊断中的应用价值. 临床肝胆病杂志, 2019, 35: 87-92.
[5] Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst, 2001, 93: 1054-1061.
[6] Marrero JA, Feng Z, Wang Y, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology, 2009, 137: 110-118.
[7] Choi J, Kim GA, Han S, et al. Longitudinal assessment of three serum biomarkers to detect very early-stage hepatocellular carcinoma. Hepatology, 2019, 69: 1983-1994.
[8] 姚明解, 陈华楠, 钱相君, 等. 乙型肝炎病毒感染相关肝癌患者术前异常凝血酶原和甲胎蛋白水平对其预后影响的研究. 中国实用内科杂志, 2019, 39: 67-70.
[9] Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: A meta-analysis. Gastroenterology, 2018, 154: 1706-1718.e1701.
[10] Kudo M, Izumi N, Ichida T, et al. Report of the 19th follow-up survey of primary liver cancer in Japan. Hepatol Res, 2016, 46: 372-390.
[11] Qu C, Wang Y, Wang P, et al. Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy. Proc Natl Acad Sci U S A, 2019, 116: 6308-6312. |
